The Association between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Noam Barda; Michal Canetti; Mayan Gilboa; Keren Asraf; Victoria Indenboim; Yael Weiss-Ottolenghi; Sharon Amit; Daniel Zubli; Ram Doolman; Ella Mendelson; Laurence S. Freedman; Yitshak Kreiss; Yaniv Lustig; Gili Regev-Yochay

doi:10.1093/cid/ciac886

The Association between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Noam Barda, Michal Canetti, Mayan Gilboa, Keren Asraf, Victoria Indenboim, Yael Weiss-Ottolenghi, Sharon Amit, Daniel Zubli, Ram Doolman, Ella Mendelson, Laurence S. Freedman, Yitshak Kreiss, Yaniv Lustig, Gili Regev-Yochay

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

The correlation between anti–severe acute respiratory syndrome coronavirus 2 antibody levels and infection was reported. Here, we estimated the role of pre–fourth dose levels using data from 1098 healthcare workers. The risk of infection was reduced by 46% (95% confidence interval, 29%–59%) for each 10-fold increase in prebooster levels. Prebooster antibody levels could be used to optimally time boosters.

Original language	English
Pages (from-to)	1315-1317
Number of pages	3
Journal	Clinical Infectious Diseases
Volume	76
Issue number	7
DOIs	https://doi.org/10.1093/cid/ciac886
State	Published - 3 Apr 2023
Externally published	Yes

Bibliographical note

Publisher Copyright:
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved.

Funding

Potential conflicts of interest. G. R.-Y. reports institutional grant funding of studies not related to the current study from Pfizer and Moderna; and consulting fees/honoraria from Teva, MSD, AstraZeneca, Pfizer, Moderna, and Medison. N. B. and Y. L. report institutional grants from Pfizer and Moderna. Y. L. reports an investigator-initiated grant from Pfizer, unrelated to this work. Y. K. reports other financial or nonfinancial interests as a lecturer in Tel Aviv University—as a faculty and as guest lecturer in Reichman University. All other authors report no potential conflicts. We thank the Sheba healthcare workers participating in the trial for their full cooperation. We thank the Sheba management, particularly Dr Amir Grinberg, Bella Ben Mordechai, and their team for their assistance; Vered Roa, Amit Orgad, and Yael Beker-Ilani for coordinating the study, recruitment and follow-up; and the laboratory team for their efforts: Ravit Koren, Tal Levin, Osnat Halpern, Yara Kanaaneh, Shiri Kats-Likvornik, Alex Aydenzon, Hanaa Jaber, and Lilac Or. This study was internally funded by Sheba Medical Center. Y. L. is a recipient of the Nehemia Rubin Excellence in Biomedical Research, the TELEM Program of Chaim, Sheba Medical Center.

Funders	Funder number
Nehemia Rubin Excellence in Biomedical Research
TELEM Program of Chaim, Sheba Medical Center
Pfizer
Sheba Medical Center

Keywords

IgG levels
SARS-CoV-2
boosters
infection risk
mRNA vaccines

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/cid/ciac886

Cite this

Barda, N., Canetti, M., Gilboa, M., Asraf, K., Indenboim, V., Weiss-Ottolenghi, Y., Amit, S., Zubli, D., Doolman, R., Mendelson, E., Freedman, L. S., Kreiss, Y., Lustig, Y., & Regev-Yochay, G. (2023). The Association between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Clinical Infectious Diseases, 76(7), 1315-1317. https://doi.org/10.1093/cid/ciac886

@article{b57e4bb694e6494eaa543fe1fc5f9c7a,

title = "The Association between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection",

abstract = "The correlation between anti–severe acute respiratory syndrome coronavirus 2 antibody levels and infection was reported. Here, we estimated the role of pre–fourth dose levels using data from 1098 healthcare workers. The risk of infection was reduced by 46% (95% confidence interval, 29%–59%) for each 10-fold increase in prebooster levels. Prebooster antibody levels could be used to optimally time boosters.",

keywords = "IgG levels, SARS-CoV-2, boosters, infection risk, mRNA vaccines",

author = "Noam Barda and Michal Canetti and Mayan Gilboa and Keren Asraf and Victoria Indenboim and Yael Weiss-Ottolenghi and Sharon Amit and Daniel Zubli and Ram Doolman and Ella Mendelson and Freedman, {Laurence S.} and Yitshak Kreiss and Yaniv Lustig and Gili Regev-Yochay",

year = "2023",

month = apr,

day = "3",

doi = "10.1093/cid/ciac886",

language = "אנגלית",

volume = "76",

pages = "1315--1317",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "7",

}

Barda, N, Canetti, M, Gilboa, M, Asraf, K, Indenboim, V, Weiss-Ottolenghi, Y, Amit, S, Zubli, D, Doolman, R, Mendelson, E, Freedman, LS, Kreiss, Y, Lustig, Y & Regev-Yochay, G 2023, 'The Association between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection', Clinical Infectious Diseases, vol. 76, no. 7, pp. 1315-1317. https://doi.org/10.1093/cid/ciac886

TY - JOUR

T1 - The Association between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

AU - Barda, Noam

AU - Canetti, Michal

AU - Gilboa, Mayan

AU - Asraf, Keren

AU - Indenboim, Victoria

AU - Weiss-Ottolenghi, Yael

AU - Amit, Sharon

AU - Zubli, Daniel

AU - Doolman, Ram

AU - Mendelson, Ella

AU - Freedman, Laurence S.

AU - Kreiss, Yitshak

AU - Lustig, Yaniv

AU - Regev-Yochay, Gili

PY - 2023/4/3

Y1 - 2023/4/3

N2 - The correlation between anti–severe acute respiratory syndrome coronavirus 2 antibody levels and infection was reported. Here, we estimated the role of pre–fourth dose levels using data from 1098 healthcare workers. The risk of infection was reduced by 46% (95% confidence interval, 29%–59%) for each 10-fold increase in prebooster levels. Prebooster antibody levels could be used to optimally time boosters.

AB - The correlation between anti–severe acute respiratory syndrome coronavirus 2 antibody levels and infection was reported. Here, we estimated the role of pre–fourth dose levels using data from 1098 healthcare workers. The risk of infection was reduced by 46% (95% confidence interval, 29%–59%) for each 10-fold increase in prebooster levels. Prebooster antibody levels could be used to optimally time boosters.

KW - IgG levels

KW - SARS-CoV-2

KW - boosters

KW - infection risk

KW - mRNA vaccines

UR - http://www.scopus.com/inward/record.url?scp=85143085583&partnerID=8YFLogxK

U2 - 10.1093/cid/ciac886

DO - 10.1093/cid/ciac886

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 36366729

AN - SCOPUS:85143085583

SN - 1058-4838

VL - 76

SP - 1315

EP - 1317

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 7

ER -

The Association between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Abstract

Bibliographical note

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this